Walk around any pharma manufacturing conference this year and the word "peptide" comes up in almost every conversation — usually in the same breath as GLP-1.
That's understandable, notes Sajeev Emmanuel Medikonda, Corporate Planning and Strategy at Neuland Laboratories.
The commercial success of weight-loss and diabetes peptides has triggered a wave of capacity investment throughout the CDMO sector.
Solid-phase and liquid-phase synthesis lines are being built at a scale that would have seemed implausible a decade ago.
But there’s a risk associated with letting one drug class define how an entire industry thinks about peptide manufacturing.
The molecules now moving through clinical development look quite different … and the infrastructure best suited to one doesn’t necessarily suit the other.
The pipeline behind the GLP-1 headlines has grown dramatically in both size and breadth.
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.
Subscribe now Already a subscriber? Sign in here.
